Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

• Status: Recruiting
• Trial end date: 2024-06-20
• Target enrollment: 0
• Participant gender: All

Summary

This prospective，multi-center，open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital

Criteria

Inclusion Criteria:

• Pathologically confirmed peripheral T-cell lymphoma based on 2016 WHO classification with enough tumor sample for NGS

• Treatment naive

• Age ≥ 18 years

• Must has measurable lesion in CT or PET-CT prior to treatment

• ECOG 0,1,2

• Informed consented

Exclusion Criteria:

• ALCL,ALK positive, NK/T-cell leukemia, adult T-cell lymphoma/leukemia, T-LGL

• Has accepted localized or systemic anti-lymphoma treatment

• Has accepted autologous Stem cell transplantation before

• History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix prior to study treatment

• Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease

• Primary CNS lymphoma

• Left EF≤ 50%

• Lab at enrollment (Unless caused by lymphoma): Neutrophile<1.5*10^9/ L ;Platelet<50*10^9/L; ALT or AST >2*ULN; Creatinine>1.5*ULN

• Other uncontrollable medical condition that may that may interfere the participation of the study

• Not able to comply to the protocol for mental or other unknown reasons

• Patients with mentally disorders or other reasons unable to fully comply with the study protocol

• Pregnant or lactation

• HIV infection

• HBV-DNA or HCV-RNA positive